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We investigated the clinicopathologic and oncoprotein expression characteristics of 11 pure mucinous and
76 non-mucinous infiltrating ductal carcinomas in the human female breast. We compared patient age,
tumor size, axillary lymph node status, and the expression of estrogen receptor (ER), progesterone receptor
(PR), deleted-in-colon cancer (DCC), HER-2/neu, and p53. Mucinous carcinoma with axillary lymph node
metastasis occurs less frequently than non-mucinous carcinoma (0% vs 63.1%; p = 0.0018). Compared with
the non-mucinous type, mucinous carcinoma specimens have more DCC expression (100% vs 48.7%;
p = 0.0027) and more ER expression (90.9% vs 26.9%; p = 0.0023), but less HER-2/neu overexpression
(0% vs 38.1%; p = 0.0302). We confirmed that mucinous carcinoma samples from the breast reveal distinct
clinicopathologic and oncoprotein expression features compared with non-mucinous carcinoma and,
therefore, it seems reasonable to suggest different biologic characteristics and manifestations.
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Genetic alterations are frequently associated with neoplasia.
The activation of proto-oncogenes and the inactivation of
tumor-suppressor genes may be responsible for oncogenesis,
and many of the tumor-suppressor genes that have been
isolated have demonstrated a loss of heterozygosity (LOH)
in several types of human neoplasia [1].
The candidate tumor-suppressor gene DCC (deleted-
in-colon cancer) was isolated by Fearon et al, who mapped
an allelic deletion to chromosome 18q 21.3 in colorectal
carcinoma [2]. DCC expression is reduced or absent in 88%
of various colorectal carcinoma cell lines and in 70% of
colorectal cancers [2,3], which is consistent with a tumor-
suppressive function of the gene product. There is decreased
expression of DCC mRNA in human colorectal cancers and
an association with both prognosis and the probability of
distant metastasis [4,5].
LOH in 18q is reported in approximately 40% of breast
cancers, but this does not always include the DCC locus.
LOH at the DCC locus was detected in 52% of patients with
breast cancer, and 77% of these had a distinct reduction in,
or total loss of, DCC expression [6]. The reduction in the
expression of the DCC-gene protein in breast cancer is
approximately 50% [7,8]. These findings indicate that DCC
plays an important role in the oncogenesis of breast cancer.
The p53 tumor-suppressor gene encodes a DNA-binding
nuclear protein that appears to inhibit the progression of a
cell from G1 to S phase [9]. Expression of the p53 protein in
breast cancer has prognostic significance [10]. The HER-2/
neu proto-oncogene, located on chromosome 17q 21.2–q12,
codes for a 185-kDa transmembrane growth factor receptor
and is amplified and/or overexpressed in approximately
25% of breast carcinomas; it is associated with poor patient
prognosis [11].
Breast cancer is a heterogeneous disease with regards to
morphology, invasive behavior, metastatic capacity, hor-
mone expression, oncogene and tumor-suppressor gene
expression, and clinical outcome. Mucinous carcinoma is a
specific histologic type of breast cancer characterized by
abundant extracellular mucin. The reported frequency of
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mucinous carcinoma of the breast is about 1–6% of all breast
cancers [12,13]. It is generally thought that the tumor is
more prevalent in older women and has a better prognosis
than the more common ductal breast cancer [14,15].
To evaluate and compare the clinicopathologic and
oncoprotein expression characteristics of mucinous and
non-mucinous invasive breast cancers, we used immuno-
histochemical staining with monoclonal antibodies to
estrogen receptor (ER), progesterone receptor (PR), and p53
and polyclonal antibodies to HER-2/neu and DCC. The
results revealed that mucinous carcinoma has distinct
histopathologic and oncoprotein expression characteristics
compared with non-mucinous carcinoma.
MATERIALS AND METHODS
Clinical records for patients who had been diagnosed with
primary mucinous carcinoma of the breast between 1990
and 1999 were accessed from Department of Pathology files
at the Buddhist Tzu Chi General Hospital. Carcinomas
were histologically verified as mucinous when nearly all
the tumor cells were suspended in abundant extracellular
mucin. In total, there were 11 pure mucinous carcinomas.
Seventy-six non-mucinous infiltrating ductal carcinomas
were randomly selected for comparison. Clinicopathologic
factors recorded were age, tumor size, and pathologically
verified lymph node status.
Immunohistochemical staining
Rabbit polyclonal anti-chicken DCC antibody (anti-cDCC),
donated by Dr. Chuong, was developed using in vitro
immunization with synthesized peptide as an antigen, as
described previously [16]. The antigenic peptide was de-
signed from codons 721–730 (DESVPDQPS) of the third
fibronectin type III domain of the DCC gene.
Rabbit polyclonal anti-HER-2/neu antibody and mouse
monoclonal anti-ER, anti-PR, and anti-p53 antibodies were
ordered from Dako (Copenhagen, Denmark).
Individual tissue sections of 4–5 µm were deparaffinized
and heated in a 10-mM citric acid monophosphate buffer
(pH 6.0) for 30 minutes in a 1.35-kW microwave oven at
high power [17]. This method of enhancing the recognition
of antigen in archival tissue is termed antigen retrieval. To
minimize the evaporation of buffer during heating, the
tissue slides were microwaved in a nonmetallic kitchen
pressure cooker. Immunohistochemical staining was per-
formed with labeled streptavidin from a complex kit (Dako).
This immunohistochemical technique involved the
sequential application of the following antibodies: pri-
mary rabbit anti-DCC (1:300), mouse anti-ER (1:100), mouse
anti-PR (1:50), rabbit anti-HER-2/neu (1:200), mouse anti-
p53 (1:100), biotinylated anti-rabbit and anti-mouse sec-
ond antibodies (Dako; 30 minutes), and a tertiary strep-
tavidin peroxidase (Dako; 30 minutes). Antibody incu-
bation was followed by tissue-section rinse in phosphate-
buffered saline, repeated three times (5 minutes each). All
slides were stained with all antibodies simultaneously, as
described here.
Following treatment with chromogen-3-amino-9-ethyl
carbazole (AEC), the sites of immunoprecipitate formation
were identified by light microscopy. Positive and negative
control sections were included with each assay. Samples
were regarded as positive for DCC when at least 25% of tu-
mor cells were assessed as granular cytoplasmic immuno-
reactive, but this classification proved redundant, since
staining for DCC turned out to be an all-or-nothing
phenomenon [18]. Membrane staining was interpreted as
HER-2/neu oncoprotein expression, with the amount of
staining scored in a blinded fashion as negative (no
immunostaining), trace positive (a few immunostained cells
scattered throughout the tumor or located along one edge
of the specimen), moderate (distinct membrane staining in
most cells), or strong (intense membrane staining in most
cells) [19]. Overexpression was defined as moderate or
strong membrane immunostaining, as previously described
[11]. Immunostaining for ER, PR, and p53 was regarded as
positive when at least 25% of tumor cells were nuclear
immunoreactive.
Statistical analysis
Associations of mucinous and non-mucinous carcinomas
with DCC expression and other tumor characteristics were
calculated using Chi-squared or Fisher’s exact tests. A two-
tailed p of less than 0.05 was considered statistically
significant.
RESULTS
The clinicopathologic and oncoprotein expression
characteristics of 11 mucinous carcinomas and 76 non-
mucinous infiltrating ductal carcinomas are listed in the
Table. Age and tumor size were not significantly different
in the two carcinoma types. Mucinous carcinoma with
axillary lymph node metastasis occurred less frequently
than non-mucinous carcinoma (0% vs 63.1%; p = 0.0018).
There was greater ER expression in mucinous carcinoma
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(90.9% vs 26.9%; p = 0.0023) but there was no difference in
PR expression (54.5% mucinous vs 47.3% non-mucinous;
p = 0.6562).
p53 protein expression was lower in mucinous than
non-mucinous carcinomas (9.1% vs 34.2%) (Figure 1), but
the result was not significant (p = 0.1821). The most significant
finding was that all 11 mucinous carcinomas had DCC
protein expression (Figure 2), compared with 48.7% of non-
mucinous carcinomas. In addition, none of the 11 mucinous
carcinomas had HER-2/neu overexpression, while 38.1%
of non-mucinous carcinomas revealed HER-2/neu onco-
protein overexpression.
DISCUSSION
Evidence has been accumulating that tumors show alter-
ations in oncoprotein expression, which may be caused by
genetic mutation or modulation of oncogenesis [1]. We
found a very high frequency (100%) of strong DCC protein
expression in mucinous carcinoma compared with non-
mucinous infiltrating ductal carcinoma of the breast. This
implies that there is no loss of DCC protein expression in
Table. Expression of p53, DCC, and HER-2/neu in mucinous carcinoma of the breast
Mucinous Non-mucinous
carcinoma (n = 11) carcinoma (n = 76)
Age (yr), n (%) 0.5979
≥ 50 6 (54.5) 35 (46.0)
< 50 5 (45.5) 41 (54.0)
Mean 52 50
Tumor size (cm), n (%) 0.7197
≤ 5 cm 8 (72.8) 56 (73.7)
> 5 cm 3 (27.2) 20 (26.3)
Mean 3.5 4.5
Axillary node status, n (%) 0.0018
Positive 0 (0) 48 (63.1)
Negative 11 (100) 28 (26.9)
Estrogen receptor, n (%) 0.0023
Positive 10 (90.9) 28 (26.9)
Negative 1 (9.1) 48 (63.1)
Progesterone receptor, n (%) 0.6562
Positive 6 (54.5) 36 (47.3)
Negative 5 (45.5) 40 (52.7)
p53 overexpression, n (%) 0.1821
Positive 1 (9.1) 26 (34.2)
Negative 10 (90.9) 50 (65.8)
DCC expression, n (%) 0.0027
Positive 11 (100) 37 (48.7)
Negative 0 (0) 39 (51.3)
HER-2/neu overexpression, n (%) 0.0302
Positive 0 (0) 29 (38.1)
Negative 11 (100) 47 (61.9)
*Mucinous vs non-mucinous carcinoma, Chi-squared test.
Figure 1. Immunohistochemical staining for p53 reveals nuclear staining
in mucinous carcinoma (3-amino-9-ethyl carbazole, × 400).
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mucinous breast cancer and suggests that loss of DCC
protein is unlikely to play a major role in the carcinogenesis
of mucinous carcinoma of the breast. This finding is in
agreement with an earlier study of mucinous carcinoma of
the colorectum [20]. In addition, both breast and colorectal
mucinous carcinomas do not exhibit 18q LOH, suggesting
that mucinous carcinoma may differ genetically from non-
mucinous carcinoma [20].
In another study, strong DCC expression was found in
mucinous adenocarcinoma of the cervix [21], indicating
that DCC expression is related to mucinous differentiation.
Our results reconfirm this association. Research examining
DCC expression in mucinous carcinoma of different organs
(ovary and pancreas) is planned for the near future to
further investigate this association.
To address such a scenario, a genetic model for multistep
alterations in relevant oncogenes and associated allelic
losses in colorectal tumorigenesis has been advocated [1].
Concordant p53, DCC, and c-ki-ras alterations are associated
with increased frequency of metastasis in colorectal
carcinoma. A variety of genetic changes in breast cancer,
including oncogene amplification (HER-2/neu, int-2, c-myc,
H-ras) and deletion or mutation in tumor-suppressor genes
(RB, p53) have also been reported [22,23]. The results of this
study revealed no overexpression of HER-2/neu and a low
frequency (9.1%) of p53 expression, further suggesting that
these two genes are rarely involved in tumorigenesis of
mucinous breast cancer, which may contribute to the better
prognosis in these cancers [10,11]. Our research confirms
findings from previous studies demonstrating a high
frequency of ER expression (90.9%) in mucinous breast
cancer [24,25].
In conclusion, mucinous carcinomas of the breast present
less axillary lymph node metastasis, retain expression of
DCC protein, demonstrate frequent expression of ER and a
low frequency of p53 overexpression, and are negative for
HER-2/neu overexpression. We suggest that these
characteristics may offer an explanation for the better
prognosis established for patients diagnosed with mucinous
carcinoma of the breast compared with non-mucinous
infiltrating ductal carcinoma.
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